Document is current
Any future updates will be listed below
-
Authors
Bonaventura, Jordi https://orcid.org/0000-0002-4745-0151
Lam, Sherry
Carlton, Meghan
Boehm, Matthew A.
Gomez, Juan L.
Solís, Oscar
Sánchez-Soto, Marta
Morris, Patrick J.
Fredriksson, Ida
Thomas, Craig J.
Sibley, David R. https://orcid.org/0000-0002-0624-962X
Shaham, Yavin https://orcid.org/0000-0002-8242-3319
Zarate, Carlos A. Jr
Michaelides, Michael https://orcid.org/0000-0003-0398-4917
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA000069)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
- License Information
-
More Information
Article History
Received: 27 October 2020
Revised: 25 March 2021
Accepted: 30 March 2021
First Online: 15 April 2021
Compliance with ethical standards
:
: CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as co-inventor on a patent for the use of (2R,6R)- hydroxynorketamine, (S)-dehydronorketamine, and other stereo- isomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors declare no conflict of interest.
